Navigation Links
Chimerix Initiates a Multi-dose Clinical Trial of the Company's Lead Compound, CMX001, for the Treatment for Smallpox Infection
Date:12/11/2007

RESEARCH TRIANGLE PARK, N.C., Dec. 11 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has initiated a multi-dose trial with its lead drug candidate, CMX001, an oral treatment for smallpox infection. This trial will study the pharmacokinetics and safety of three doses of the drug given to healthy volunteers.

"The high oral availability demonstrated by CMX001 in the Phase I trial has validated the utility of the company's lipid technology, ProLipTag(TM) and creates optimism for the potential of this drug candidate," said Dr. George Painter, Chimerix President and CEO. "In addition to smallpox, we believe that CMX001 has great potential in treating other serious infections such as human papillomavirus and cytomegalovirus."

CMX001 is being developed for the treatment of smallpox infection and other double stranded DNA virus infections that cause significant human morbidity and mortality. A safe, orally active antiviral drug for smallpox is needed to provide a means of treating people who become ill post exposure to the disease or who cannot be vaccinated. Chimerix has previously demonstrated that single doses of CMX001 provided excellent drug exposure and were well tolerated in healthy volunteers. CMX001 is being developed for smallpox under a licensing agreement with Gilead Sciences, Inc. The work is partially funded by a $36.1 million grant awarded to the company by the National Institutes of Allergy and Infectious Disease.

About Chimerix

Chimerix, Inc. discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid, prodrug technology, ProLipTag(TM), Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
6. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. Prolexys Pharmaceuticals Initiates Phase 1 Study
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Little Rock, AR (PRWEB) , ... October 13, ... ... owned firm with locations throughout Arkansas that offers insurance and financial preparation services, ... to benefit the Rock City Rescue organization. , Rock City Rescue is a ...
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
Breaking Medicine News(10 mins):